Plans are in place for a Guardant360-based assay to predict response to AsztraZeneca's Tagrisso and for a blood-based TMB test using the larger GuardantOmni panel.
At the conference, researchers presented data from a number of studies using molecular diagnostic tools to better characterize breast cancer recurrence and treatment outcomes.
At the Business in Personalized Medicine Summit last week, the company also said it has generated promising data from a pilot study for early detection of lung cancer.
Following recent publications and anticipating the readout from its NILE study next year, the company plans to make the case that its liquid biopsy approach performs as well as tissue tests.
The company reported revenues of $21.7 million compared to $11.1 million in the year-ago quarter, overshooting analysts' expectations of $17.5 million.
Guardant's lab will make Guardant360 available to doctors and their patients in the region to help identify patients eligible for molecularly targeted drugs.
The study supports the use of liquid biopsy tests to guide treatment decisions, especially in patients who can't be biopsied, or don't have enough tissue available for standard testing.
The expected gross proceeds are more than double what the firm proposed as its original goal for the offering when it filed plans to list its shares in September.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
